Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?

Key Takeaways IBRX is expanding Anktiva beyond NMIBC into broader oncology indications to drive growth.Studies include bladder cancer, NSCLC, pancreatic and other tumors using combo therapies.Strong competition from Merck, Bristol Myers and Roche may challenge market penetration.ImmunityBio’s (IBRX) growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, beyond its initial approval in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). While the current ...